Core Patent Expiration for Semaglutide
Novo Nordisk holds the primary composition-of-matter patent for semaglutide (US Patent 8,129,343), which covers the active ingredient in drugs like Ozempic and Wegovy. This patent expires on January 4, 2032 in the US.[1]
When Do Ozempic and Wegovy Patents Expire?
Ozempic (semaglutide injection for diabetes) has its main patent (8,129,343) expiring January 4, 2032, but faces multiple secondary patents and exclusivities extending protection:
- Formulation patents (e.g., US 8,536,129 for auto-injector) expire December 29, 2031.
- Pediatric exclusivity adds six months, pushing some protections to mid-2032.
- FDA Orange Book lists ~15 patents total, with the latest expiring March 2033.[1][2]
Wegovy (higher-dose semaglutide for weight loss) aligns with similar timelines, main patent to 2032, but Novo lists expirations up to 2034 for device-related patents.[1]
Why Multiple Patents and Delays?
Novo layers patents on formulations, devices, and methods-of-use to block generics. Ongoing Paragraph IV challenges from Teva, Mylan, and others could shorten this via litigation—first suits filed in 2024, with FDA tentative approvals possible by 2026 if successful.[1][3]
Biosimilar Entry Timeline
No true generics yet due to biologic-like complexity, but biosimilars might launch post-2032 if challenges win. EU patents expire earlier (2026 for some), allowing compounded versions there already.[1][2]
Impact on Pricing and Alternatives
Post-patent, prices could drop 80-90% like other GLP-1s. Until then, tirzepatide (Mounjaro/Zepbound, Lilly) patents expire later (2035+), serving as a competitor.[1][4]
[1]: DrugPatentWatch.com - Semaglutide Patents
[2]: FDA Orange Book - Ozempic
[3]: FDA Paragraph IV Database
[4]: DrugPatentWatch.com - Tirzepatide